<DOC>
	<DOC>NCT01497262</DOC>
	<brief_summary>This 4 month, open-label study will evaluate the safety and tolerability of fingolimod 0.5 mg in patients with relapsing-remitting multiple sclerosis (RRMS) and generate additional data in Multiple Sclerosis (MS) patient population that closely resembles the clinical population seen in routine medical care.</brief_summary>
	<brief_title>Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients with relapsing remitting Multiple Sclerosis Patients with Expanded Disability Status Scale (EDSS) score of 06.5. Patients with MS other than relapsing remitting MS Patients with a history of chronic disease of the immune system other than MS, which requires systemic immunosuppressive treatment, or a known immunodeficiency syndrome. Patients who have been treated with: systemic corticosteroids or immunoglobulins within 1 month prior to baseline; immunosuppressive medications within 3 months prior to baseline; monoclonal antibodies within 3 months prior to baseline; cladribine, mitoxantrone or alemtuzumab at any time. Uncontrolled diabetes mellitus at screening Diagnosis of macular edema during Screening Phase Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or to have positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests. Patients who have received total lymphoid irradiation or bone marrow transplantation. Patients with certain cardiovascular conditions and/or findings in the screening ECG Patients with certain liver conditions Pregnant confirmed by a positive pregnancy test t or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing-Remitting</keyword>
</DOC>